16 July 2021

TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused on drug development using novel targeted immunotherapies. The principal technology is the CTPIC technology platform that utilizes a proprietary non-viral vector to target and destroy cancer cells that overexpress certain receptors. VISCHER has advised TargImmune with a team led by Matthias Staehelin with Francesca Pesenti and Nicolai Bleskie (all Corporate/M&A).

Media Release

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital

You are currently offline. Some pages or content may fail to load.